CN Bio announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.
Eli Lilly has agreed to acquire US-based gene therapy company Prevail Therapeutics for an aggregate value of up to $1.04bn.
Eureka Therapeutics announced successful preclinical results from its InvisiMask Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.
Private investment organisation EQT IX has offered to acquire Swedish contract development and manufacturing organisation (CDMO) Recipharm for $2.1bn.
AstraZeneca has agreed to acquire US-based biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn.
Gilead Sciences and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash.
Boehringer Ingelheim has agreed to acquire clinical-stage Swiss biotechnology company NBE-Therapeutics for €1.18bn for enhancing its cancer pipeline portfolio.
Cybin, a life sciences company focused on psychedelic pharmaceutical therapies, today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. (“Adelia”) for up to CDN$20,161,575 (approximately $15.75m) in an all-stock transaction (the “Transaction”).
Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO).
Janssen Pharmaceuticals, a part of Johnson & Johnson, has acquired rights to investigational eye-disorder gene therapy called HMR59 from Hemera Biosciences for an undisclosed sum.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.